Financial Instruments and Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:


	September 30, 2022 (Successor)		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	33.4	$	21.7	$	11.7	$	—
Equity securities	17.2		17.2		—		—
	$	50.6	$	38.9	$	11.7	$	—
Liabilities:
Deferred compensation liabilities	$	24.1	$	—	$	24.1	$	—
Contingent consideration liabilities	6.0		—		—		6.0
	$	30.1	$	—	$	24.1	$	6.0


	December 31, 2021 (Predecessor)		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	38.7	$	24.9	$	13.8	$	—
Equity securities	36.5		36.5		—		—
	$	75.2	$	61.4	$	13.8	$	—
Liabilities:
Deferred compensation liabilities	$	36.9	$	—	$	36.9	$	—
Contingent consideration liabilities	27.3		—		—		27.3

	$	64.2	$	—	$	36.9	$	27.3

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:


	Successor				Predecessor
	September 30, 2022				December 31, 2021
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1:
10.00% first lien senior secured notes due April 2025	$	473.9	$	453.0	$	495.0	$	523.7
10.00% second lien senior secured notes due April 2025	234.8		202.6		—		—

11.50% first lien senior secured notes due December 2028	650.0		586.6		—		—
10.00% second lien senior secured notes due June 2029	191.3		204.6		—		—
Revolving credit facility due February 2022	—		—		900.0		900.0
5.75% senior notes due August 2022	—		—		610.3		324.1
4.75% senior notes due April 2023	—		—		133.7		48.9
5.625% senior notes due October 2023	—		—		514.7		279.1
10.00% second lien senior secured notes due April 2025	—		—		322.9		312.7
5.50% senior notes due April 2025	—		—		387.2		211.6

Level 2:
2017 Replacement Term loan due September 2027	1,222.8		1,134.6		—		—
2018 Replacement Term loan due September 2027	327.2		301.0		—		—
9.50% debentures due May 2022	—		—		10.4		7.7
8.00% debentures due March 2023	—		—		4.4		3.2
Term loan due September 2024	—		—		1,396.5		1,309.2
Term loan due February 2025	—		—		370.7		347.7
Total Debt	$	3,100.0	$	2,882.4	$	5,145.8	$	4,267.9

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total net sales:

Successor

Predecessor

Three Months
Ended
September 30, 2022

Three Months Ended September 24, 2021

FFF Enterprises, Inc.

26.1

CuraScript, Inc.

27.0


	Successor		Predecessor
	Period from June 17, 2022 through September 30, 2022		Period from January 1, 2022 through June 16, 2022		Nine Months Ended September 24, 2021
FFF Enterprises, Inc.	25.7	%	11.8	%	*%
CuraScript, Inc.	*		15.6		25.2

* Net sales to this distributor was less than 10.0% of the Company's total net sales for the respective periods presented above.

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:


	Successor		Predecessor
	September 30, 2022		December 31, 2021
AmerisourceBergen Corporation	30.2	%	30.0	%
McKesson Corporation	15.8		15.0
FFF Enterprises, Inc.	11.5		*
CuraScript, Inc.	*		12.7

*Accounts receivable attributable to this distributor was less than 10.0% of total gross accounts receivable at the end of the respective period presented above.

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total net sales:



	Successor		Predecessor
	Three Months Ended September 30, 2022		Three Months Ended September 24, 2021
Acthar Gel	27.0	%	28.3	%
INOmax	17.3		19.4
Therakos	12.5		12.3
APAP	12.4		*


	Successor		Predecessor
	Period from June 17, 2022 through September 30, 2022		Period from January 1, 2022 through June 16, 2022		Nine Months Ended September 24, 2021
Acthar Gel	27.8	%	25.4	%	26.3	%
INOmax	17.1		19.0		21.0
Therakos	12.4		12.5		12.3
APAP	12.6		11.0		*

*Net sales attributable to this product was less than 10.0% of total net sales for the respective periods presented above.